Updates

May 24, 2022

One of the cultural pillars at RTI Health Solutions (RTI-HS) is respect for the individual. Throughout the organization, colleagues work to show respect toward others and hold themselves accountable to this principle. 

May 18, 2022

Bradley, who has been a member of ISPE since 2011, was recommended for this honor by a committee of his peers

May 5, 2022

RTI-HS has a rich history of contributing to ISPE’s mission

March 15, 2022

The recognition honors companies demonstrating exceptional leadership and a commitment to business integrity through best-in-class ethics, compliance, and governance practices 

March 1, 2022

Guidance Expanded to Reflect Developments in Reporting Economic Evaluations of Health Interventions

February 12, 2022

Most of what we know about treatments, adverse events, and the overall survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) comes from clinical trials. However, confirmatory real-world evidence, especially in the Medicare population, is limited.

January 27, 2022

Kenneth J. Rothman, DrPH, formerly Vice President of Epidemiology Research at RTI Health Solutions, has transitioned to Distinguished Fellow Emeritus after 16 years with RTI-Health Solutions.

November 11, 2021

The institute also earned a high ranking on the Military Friendly® Supplier Diversity Program list

November 2, 2021

The ways COVID-19 vaccines are being administered have changed substantially in the last few months. Issues such as mixing and matching vaccines, boosters, and vaccine use in children are fundamentally changing that landscape.

October 27, 2021

Reach out to one of our experts to learn if using the META tool is right for your product.

August 17, 2021

When a person donates blood platelets, those platelets become life-saving treatments for a variety of conditions.

July 16, 2021

The ENCePP Guide on Methodological Standards in Pharmacoepidemiology was created and is maintained by members of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)–specifically, the ENCePP Working Group 1 on Research Methods and Guidance, chaired by RTI Health

June 16, 2021

At the forefront of this cause are groups dedicated to keeping patients and the people who care for them at the center of the conversation.

May 18, 2021

Major depressive disorder (MDD) is a leading cause of disability worldwide. Understanding the impact of MDD on quality of life has become increasingly key in research.

May 4, 2021

Understanding genetic testing results is complicated, so national guidelines recommend genetic counseling for those considering or undergoing testing. In a recent study, investigators assessed how genetic counseling is utilized in patient care.

April 28, 2021

Adult vaccination rates in the US are generally low and fall short of public health goals. Given the human and economic burden of vaccine-preventable disease, understanding the factors behind these low coverage rates is critical to improving participation. 

April 6, 2021

There are 3 on-demand treatment therapies to relieve PD off-episodes. Researchers conducted a patient-preference study to understand which aspects of the treatments patients value most.

March 23, 2021

What do rapidly changing technologies mean to the collection of stated-preference studies – studies that ask individuals what they value in their health and health care?

March 12, 2021

Insights from our experiences developing medical product dossiers with key considerations for manufacturers planning to develop early dossiers for their products.

February 1, 2021

EMA has recently launched the MINERVA project aimed at strengthening the use of real-world data in medicines development. RTI Health Solutions researchers will coordinate the project.

January 26, 2021

Please join Xabier Garcia de Albeniz for this recorded 30-minute case-study workshop on the use of causal inference methods for real-world evidence.

January 25, 2021

18 years of studies has essentially ruled out any but a small potential increase in risk of osteosarcoma. Due to the strength of the findings and other post-marketing experience, the drug sponsor was able to end their post-market commitment five years ahead of schedule.

January 15, 2021

The launch of the SIGMA Consortium heralds a new era of collaboration to better understand safety and effectiveness of medical interventions. SIGMA aims to integrate expertise and data from multiple European Research Centres.

September 30, 2020

We're excited to have reached this milestone in our journey of providing uncompromisingly ethical and objective research to help our clients understand the benefits, risks, value, and potential of their products.

September 3, 2020

The best practices outlined by this draft guidance should be considered when evaluating PROs intended to support drug submissions as well as medical devices.